The Multibillion-Dollar Battle For Metsera’s Obesity DrugsLearn how the battle between Novo Nordisk and Pfizer over Metsera, a three-year-old company working on treatments for obesity and diabetes, escalated this week. https://t.co/k1NQKNo2LG ...

Obesity drugmaker Metsera has gotten higher offers from both Novo Nordisk and Pfizer in an ongoing battle for the startup. https://t.co/KqsNlCyjf5 ...

Novo will slash 11% of staff globally as it fights to recover ground lost to obesity-drug rivals. Can the pharma giant answer its critics and keep the competition at bay?🎧 Bloomberg reporters took your questions in a Live Q&A. Listen back: https://t.co/spNxngJear ...

Novo will slash 11% of staff globally as it fights to recover ground lost to obesity-drug rivals. Can the pharma giant answer its critics and keep the competition at bay?🎧 Bloomberg reporters took your questions in a Live Q&A. Listen back: https://t.co/197SIueYIm ...